Chemotherapy for endometrial cancer in adjuvant and advanced disease settings

Oncologist

Volumn 21, Issue 10, 2016, Pages 1250-1259

  Bestvina, Christine M ^a   Fleming, Gini F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemoradiotherapy; Drug therapy, adjuvant; Endometrial cancer; Local neoplasm recurrence; Metastasis, neoplasm

Indexed keywords

AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; GESTAGEN; IXABEPILONE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DOWN REGULATION; ENDOMETRIUM CANCER; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84991698526     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0062     Document Type: Article

References (104)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
2. National Cancer Institute. Previous version: SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Available at http://seer. cancer.gov/csr/1975_2012/. Accessed October 5, 2015.
3. Hamilton CA, Cheung MK, Osann K et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94:642–646.
4. Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 2008; 100:1707–1716.
5. National Comprehensive Cancer Network. Uterine neoplasms. Available at http://www.nccn.org/ professionals/physician_gls/pdf/uterine.pdf. Accessed November 1, 2015.
6. Amant F, Mirza MR, Koskas M et al. Cancer of the corpus uteri. Int J Gynaecol Obstet 2015;131(suppl 2): S96–S104.
7. Poulsen H, Jacobsen M, Bertelsen K et al. Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low risk cases. Int J Gynecol Cancer 1996;6:38–43.
8. Martin-Hirsch PP, Bryant A, Keep SL et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011;6 CD001040.
9. Kong A, Johnson N, Kitchener HC et al. Adjuvant radiotherapy for stage I endometrial cancer: An updated Cochrane systematic review and metaanalysis. J Natl Cancer Inst 2012;104:1625–1634.
10. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. PostOperative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404–1411.
11. Nout RA, Smit VT, Putter H et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 2010;375: 816–823.
12. Meyer LA, Bohlke K, Powell MA et al. Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 2015;33:2908–2913.
13. Randall ME, Filiaci VL, Muss H et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36–44.
14. Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer 2006;95:266–271.
15. Susumu N, Sagae S, Udagawa Y et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combinedchemotherapyinpatients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226–233.
16. Kuoppala T, Mäenpää J, Tomas E et al. Surgically staged high-risk endometrial cancer: Randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008; 110:190–195.
17. Hogberg T, Signorelli M, de Oliveira CF et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer 2010;46:2422–2431.
18. McMeekin DSFV, Aghajanian C, Cho J et al. Randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial. Gynecol Oncol 2014;134:438.
19. Fleming GF. Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J Clin Oncol 2007;25:2983–2990.
20. Miller D, Filiaci V, Fleming G et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771.
21. Homesley HD, Filiaci V, Gibbons SK et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol 2009;112:543–552.
22. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.
23. McConechy MK, Talhouk A, Leung S et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res 2016;22:2865–2873.
24. McMeekin DS, Filiaci VL, Thigpen JT et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study. Gynecol Oncol 2007;106:16–22.
25. Creutzberg CL, de Boer SM, Putter H et al. Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial. J Clin Oncol 2015;33 (suppl):abstr 5501.
26. Mountzios G, Pectasides D, Bournakis E et al. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol 2011;79: 278–292.
27. Singh M, Zaino RJ, Filiaci VJ et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325–333.
28. Ma BB, Oza A, Eisenhauer E et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004;14:650–658.
29. Thigpen JT, Blessing JA, DiSaia P et al. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone receptor levels—The Gynecologic Oncology Group experience. In: Baulier E, Iacobelli S,McGuireW, eds. Endocrinology and Malignancy. Pearl River, NY: Parthenon Publishers, 1986:446–454.
30. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736–1744.
31. Thigpen T, Brady MF, Homesley HD et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2001;19:364–367.
32. McMeekin DS, Gordon A, Fowler J et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003; 90:64–69.
33. Rose PG, Brunetto VL, VanLe L et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2000;78: 212–216.
34. Covens AL, Filiaci V, Gersell D et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2011;120:185–188.
35. Emons G, Günthert A, Thiel FC et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Gynecol Oncol 2013;129:495–499.
36. Gallagher CJ, Oliver RT, Oram DH et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 1991;98:1037–1041.
37. Jeyarajah AR, Gallagher CJ, Blake PR et al. Longterm follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996;63:47–52.
38. Lhommé C, Vennin P, Callet N et al.Amulticenter phase II studywith triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation Study. Gynecol Oncol 1999;75:187–193.
39. Asbury RF, Brunetto VL, Lee RB et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol 2002;25:557–560.
40. Pandya KJ, Yeap BY, Weiner LM et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: An Eastern CooperativeOncology Group Study (E4882). Am J Clin Oncol 2001;24:43–46.
41. Whitney CW, Brunetto VL, Zaino RJ et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92:4–9.
42. Fiorica JV, Brunetto VL, Hanjani P et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10–14.
43. Thigpen JT, Blessing JA, DiSaia PJ et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408–1414.
44. van Wijk FH, Aapro MS, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003;14:441–448.
45. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2004;22: 3902–3908.
46. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin 1 cisplatin versus doxorubicin 1 24-h paclitaxel 1 filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study. Ann Oncol 2004;15:1173–1178.
47. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159–2166.
48. Dimopoulos MA, Papadimitriou CA, Georgoulias V et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study. Gynecol Oncol 2000;78:52–57.
49. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study. J Clin Oncol 2001;19:4048–4053.
50. Pignata S, Scambia G, Pisano C et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer 2007;96:1639–1643.
51. Aghajanian C, Filiaci VL, Dizon DS et al. A randomized phase II study of paclitaxel/carboplatin/ bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy formeasurable stage III or IVA, stage IVB or recurrent endometrial cancer,GOG-86P. J Clin Oncol 2015;33(suppl):abstr 5500.
52. Lorusso D, Ferrandina G, Colombo N et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer:TheMITOEND-2trial. J Clin Oncol 2015;33 (suppl):abstr 5502.
53. Homesley HD, Meltzer NP, Nieves L et al. A phase II trial of weekly 1-hour paclitaxel as secondline therapy for endometrial and cervical cancer. Int J Clin Oncol 2008;13:62–65.
54. Lincoln S, Blessing JA, Lee RB et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003;88:277–281.
55. Lissoni A, Zanetta G, Losa G et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996;7:861–863.
56. Markman M, Blessing J, Rubin SC et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436–440.
57. Fracasso PM, Blessing JA, Molpus KL et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006;103: 523–526.
58. Gupta D, Owers RL, Kim M et al. Aphase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 2009;113:327–330.
59. Miller DS, Blessing JA, Lentz SS et al. A phase II trial of topotecan in patients with advanced, persistent, or recurrentendometrial carcinoma:A Gynecologic Oncology Group study. Gynecol Oncol 2002;87:247–251.
60. Muggia FM, Blessing JA, Sorosky J et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer:A Gynecologic Oncology Group study. J Clin Oncol 2002;20:2360–2364.
61. Rose PG, Blessing JA, Lewandowski GS et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996;63:101–104.
62. Pawinski A, Tumolo S, Hoesel G et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: A randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol 1999;86:179–183.
63. Miller DS, Blessing JA, Drake RD et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115: 443–446.
64. Tait DL, Blessing JA, Hoffman JS et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2011;121:118–121.
65. Sutton GP, Blessing JA, Homesley HD et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994;73: 1453–1455.
66. Dizon DS, Blessing JA, McMeekin DS et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol 2009;27:3104–3108.
67. McMeekin S, Dizon D, Barter J et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol 2015;138:18–23.
68. Nagao S, Nishio S, Michimae H et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/ GOTIC-004/Intergroup study. Gynecol Oncol 2013; 131:567–573.
69. Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol Oncol 2014;133:375–381.
70. Myers AP. New strategies in endometrial cancer: Targeting the PI3K/mTOR pathway–the devil is in the details. Clin Cancer Res 2013;19:5264–5274.
71. McMeekin DS, Sill MW, Benbrook D et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. Gynecol Oncol 2007;105:508–516.
72. Nimeiri HS, Oza AM, Morgan RJ et al. A phase II study of sorafenib in advanced uterine carcinoma/ carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010; 117:37–40.
73. Aghajanian C, Sill MW, Darcy KM et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2011;29:2259–2265.
74. Coleman RL, Sill MW, Lankes HA et al. Aphase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2012; 127:538–543.
75. Vergote I, Teneriello M, Powell MA et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol 2013;31(suppl):abstr 5520.
76. Castonguay V, Lheureux S, Welch S et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014;134:274–280.
77. Powell MA, Sill MW, Goodfellow PJ et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRGOncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135: 38–43.
78. Dizon DS, Sill MW, Schilder JM et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135:441–445.
79. Bender D, Sill MW, Lankes HA et al. A phase II evaluation ofcediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/ Gynecologic Oncology Group study. Gynecol Oncol 2015;138:507–512.
80. Moore KN, Sill MW, Tenney ME et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol 2015;138:513–518.
81. Slomovitz BM, Lu KH, Johnston T et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116:5415–5419.
82. Ray-Coquard I, Favier L, Weber B et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013;108:1771–1777.
83. Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus inwomenwith recurrent ormetastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29:3278–3285.
84. Fleming GF, Filiaci VL, Marzullo B et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2014; 132:585–592.
85. Colombo N, McMeekin DS, Schwartz PE et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. Br J Cancer 2013;108:1021–1026.
86. Oza AM, Pignata S, Poveda A al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol 2015;33:3576–3582.
87. Alvarez EA, Brady WE, Walker JL et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2013;129:22–27.
88. Slomovitz BM, Jiang Y, Yates MS et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015; 33:930–936.
89. Oza AM, Eisenhauer EA, Elit L et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26: 4319–4325.
90. Fleming GF, Sill MW, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15–20.
91. Slomovitz B, Schmeler K, Miller D et al. Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Gynecol Oncol 2010;116:S2–S169.
92. Leslie KK, Sill MW, Lankes HA et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127:345–350.
93. Leslie KK, Sill MW, Fischer E et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2013;129:486–494.
94. Myers AP, Filiaci VL, Zhang Y et al. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimusandalternatingmegestrol acetate and tamoxifen foradvanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2016;141:43–48.
95. Pant A, Lee II, Lu Z et al. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One 2012;7:e41593.
96. Gu C, Zhang Z, Yu Y et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci 2011;102:557–564.
97. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 2012;366:520–529.
98. Konecny GE, Santos L, Winterhoff B et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 2009;100:89–95.
99. Clinicaltrials.gov. Evaluation of carboplatin/ paclitaxel with and without trastuzumab (Herceptin) in uterine serous cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01367002. Accessed February 12, 2016.
100. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl JMed 2009;361:123–134.
101. Reinbolt R, Hays J. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013;3:237.
102. Howitt BE, Shukla SA, Sholl LM etal. Associationof polymerase «-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015;1:1319–1323.
103. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.
104. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237–251.